NCT01413022: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma |
|
|
| Completed | 1 | 44 | US | Oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, Irinotecan, Campto, Camptosar, CPT-11, U-101440E, Leucovorin, CF, CFR, LV, Fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis, flow cytometry, immunohistochemistry staining method, immunohistochemistry, pharmacological study, pharmacological studies, PF-04136309, PF-4136309 | Washington University School of Medicine, National Cancer Institute (NCI) | Pancreatic Neoplasms | 10/13 | 09/16 | | |
